Clicking the "View this Article" button will open the issue as a resizable PDF. To take the test for
the issue, return to this Introduction page and click the "Take the Test" button. The Introduction
page will remain open after you open this issue.
You may need to re-size or close the issue in order to see the Introduction page.
From 1999 to 2017, more than 700,000 people died in the United States from a drug overdose. About 400,000 of these deaths involved both prescription and illicit opioids (eg, heroin); 218,000 deaths involved prescription opioids. In 2017 alone, there were more than 70,000 overdose deaths, with nearly 70% involving opioids. This was a 10% increase from 2016, when there were 63,632 overdose deaths and two-thirds involved opioids.
The current rise in opioid overdose deaths can be described in three distinct phases. The first phase began in 1999 following an increase in the prescribing of opioids during the 1990s, due in part to a new, patient-centered focus on relieving pain as the 5th vital sign. The second phase began in 2010, with rapid increases in overdose deaths involving heroin. The third phase began in 2013, with significant increases in overdose deaths involving synthetic opioids (eg, tramadol, fentanyl), especially illicitly manufactured fentanyl. Although the opioid overdose epidemic has evolved and worsened in recent years, provisional data from 2018 indicates potential improvements in some overdose indicators. However, a final analysis will be necessary to confirm this change.
Since 2012, opioid prescribing rates have declined, suggesting that prescribers have become more cautious in their prescribing practices. However, prescriptions for opioids continue to contribute to the epidemic, with more than 35% of all opioid overdose deaths specifically involving prescription opioids. Prescription opioid use is a risk factor for illicit drug abuse, such as with heroin or fentanyl. Evidence suggests that most individuals became addicted to illicit opioids after using prescription opioids...
This program was developed by The Rx Consultant and published by Continuing Education Network, Inc. The Rx Consultant accepts no advertising or financial support from the pharmaceutical industry and is funded solely by the purchase of programs. The Rx Consultant is dedicated to providing unbiased, balanced information to health care practitioners.
Programs developed by The Rx Consultant are written by health care providers with expertise in the topic area, peer-reviewed, extensively edited, and fact-checked. This development process was created to insure that every program presents information that is current, accurate, relevant to "real world" health care providers, and written in an easy reading, "plain English" style.
The Rx Consultant is a publication of Continuing Education Network, Inc.
ACPE Universal Activity Number: 0428-0000-19-008-H03-P
Chief Editor and CE Administrator
Terry M. Baker, PharmD
Tracy Farnen, PharmD
James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Coordinator
Associate Clinical Professor
Richard Ron Finley, B.S. Pharm.,R.Ph.
Consult Pharmacist Aging and Adult Health Services
Julio R. Lopez, PharmD, FCSHP
Adjunct Clinical Professor
Assistant Clinical Professor
Visiting Associate Professor and Lecturer
Pamela Mausner, MD
Helen Berlie, Pharm.D. CDE, BCACP
Ambulatory Care Specialist - Diabetes
Senior Editorial Advisor
Gerard Hatheway, PharmD, PhD
Belinda M. Danielson, RPh
Christopher M. DeSoto, PharmD
Angie S. Graham, PharmD
Cynthia Chan Huang, PharmD, MBA
Fred Plageman, PharmD
Editorial Advisor and Clinical Practice Consultant for Nurse Practitioners
Meuleman, RN, C, MS
Any hardware that supports Microsoft Windows, Apple Mac OS, iOS, or Android, and meets the software requirements.
Browser that supports TLS 1.1 + and PDF files.
This includes Microsoft Internet Explorer 11, Google Chrome 38, Google Android OS 5.0 Browser, Apple Safari (version 7 for desktop, 5 for mobile), Mozilla Firefox 27, newer versions of these browsers, as well as some earlier versions that may require additional configuration.
Adobe Acrobat Reader is recommended, and is required for some browsers.
Note: TLS 1.1 and 1.2 support is required for browser security. Click here for TLS browser support details.
Required. Broadband recommended. (T1, DSL, Cable, G4 or higher.)